
## Prolyl-hydroxylase domain containing protein 2: Structural insight from MD Simulations

Christian R. Wick,<sup>[a]</sup> Harald Lanig,<sup>[a]</sup> Christof Jäger,<sup>[a]</sup> Nicolai Burzlaff,<sup>[b]</sup> and Timothy Clark<sup>[a,c]</sup>

[a] Department of Chemistry and Pharmacy, Computer-Chemie-Centrum, FAU Erlangen-Nürnberg, Nägelsbachstraße 25, 91052 Erlangen [b] Department of Chemistry and Pharmacy, Institute of Inorganic Chemistry, FAU Erlangen-Nürnberg, Egerlandstraße 1, 91058 Erlangen

Prolyl-hydroxylase domain containing protein 2 (PHD2) is an iron(II), oxygen and 2-oxoglutarate (2OG) dependent dioxygenase that catalyses the hydroxylation of two proline residues (oxygen dependent degradation domains, ODDD) of the  $\alpha$ -subunit of hypoxia-inducible factor (HIF-1 $\alpha$ ), one part of an  $\alpha$ , $\beta$  heterodimeric transcription factor.[1] Hydroxylation at one ODDD triggers recognition by the Von Hippel-Lindau tumor suppressor (pVHL) protein and leads to degradation of HIF-1 $\alpha$  via the proteasome. In situations with low oxygen availability (hypoxia), HIF-1 $\alpha$  levels increase in the cytoplasm and the transcription factor can translocate into the nucleus, where it up-regulates the transcription of genes that enable mammalian cells to adapt to hypoxia (e.g. EPO, VEGF, GLUT1).[2]

We describe computational studies of the mode of action of PHD2. Long-term Molecular Dynamics (MD) Simulations were performed to investigate the rigidity of the crystallographically observed conformations of PHD2 in solution. Furthermore we describe the influence of the C-terminal ODDD on the overall behavior of the protein, including the effect of the natural ligand 2-oxoglutarate and an isoquinoline inhibitor.



- [1] J. Cassavaugh, K. M. Lounsbury, J. Cell. Biochem. 2011, 112, 735-744.
- [2] R. Chowdhury, A. Hardy, C. J. Schofield, Chem. Soc. Rev. 2008, 37, 1308-1319.